Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'

被引：0
|
作者：
Wang, Chenxi [1 ]
Tian, Huichuan [1 ]
Shang, Jin [2 ]
机构：
[1] Macau Univ Sci & Technol, Fac Chinese Med, Taipa 999078, Macao, Peoples R China
[2] Hubei Univ Tradit Chinese Med, Sch Pharm, Wuhan 430065, Peoples R China
来源：
CNS DRUGS | 2025年 / 39卷 / 02期
关键词：
D O I：
10.1007/s40263-024-01152-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [1] A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
    Kato, Masaki
    Shiosakai, Masako
    Kuwahara, Kazuo
    Iba, Katsuhiro
    Shimada, Yuki
    Saito, Mizuki
    Sekine, Daisuke
    Aoki, Kazuo
    Shiomi, Yuki
    Higuchi, Teruhiko
    CNS DRUGS, 2024, 38 (12) : 1003 - 1016
  • [2] A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
    Hobart, Mary
    Zhang, Peter
    Skuban, Aleksandar
    Brewer, Claudette
    Hefting, Nanco
    Sanchez, Raymond
    McQuade, Robert D.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (03) : 203 - 209
  • [3] Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study
    Lepola, Ulla
    Hefting, Nanco
    Zhang, Doris
    Hobart, Mary
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (10) : 1403 - 1410
  • [4] Sustained Remission With Adjunctive Brexpiprazole in Major Depressive Disorder: Post Hoc Analysis of a Long-Term, Open-Label, Extension Study
    Baker, Ross A.
    Weiss, Catherine
    Meehan, Stine R.
    Zhang, Peter
    Hobart, Mary
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S307 - S307
  • [5] Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
    Inada, Ken
    Yamada, Sakiko
    Akiyoshi, Hisashi
    Kojima, Yoshitsugu
    Iwashita, Shuichi
    Ishigooka, Jun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 2267 - 2275
  • [6] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Michael E. Thase
    Arielle D. Stanford
    Asli Memisoglu
    William Martin
    Amy Claxton
    J. Alexander Bodkin
    Madhukar H. Trivedi
    Maurizio Fava
    Miao Yu
    Sanjeev Pathak
    Neuropsychopharmacology, 2019, 44 : 2268 - 2276
  • [7] Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (06) : 445 - 453
  • [8] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Thase, Michael E.
    Stanford, Arielle D.
    Memisoglu, Asli
    Martin, William
    Claxton, Amy
    Bodkin, J. Alexander
    Trivedi, Madhukar H.
    Fava, Maurizio
    Yu, Miao
    Pathak, Sanjeev
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (13) : 2268 - 2276
  • [9] Effect of adjunctive brexpiprazole on functioning in three exploratory, open-label studies in major depressive disorder
    Baker, R.
    Matsushima, Y.
    Tsuneyoshi, K.
    Weiss, C.
    Skuban, A.
    Weiller, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S406 - S406
  • [10] A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
    Forbes, Andy
    Hobart, Mary
    Ouyang, John
    Shi, Lily
    Pfister, Stephanie
    Hakala, Mika
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (05): : 433 - 441
12345